News and Trends 11 Jan 2022 Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to develop oncology and immunology treatments. According to the deal’s terms, the partners will develop up to 15 small molecule drugs to treat cancer and immunological […] January 11, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 10 Jan 2022 Leveraging Physics and Quantum Computing to Accelerate Drug Discovery Novel computational techniques are revolutionizing the way we discover new drugs. Robert Marino, CEO and co-founder of Qubit Pharmaceuticals, discusses the potential of physics to accelerate drug discovery. Paris-based Qubit Pharmaceuticals was established in 2020 to commercialize the work of leading researchers in the computational chemistry space. This field uses computer modeling to predict how […] January 10, 2022 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2021 UK Startup Lands €5M Seed Round to Produce Gene-Edited Crops with AI Phytoform, a London- and Boston-based startup, has received a €5M ($5.7M) investment to develop gene-edited crops with the help of artificial intelligence tools. The firm expects to bring its first product, a weather-resistant tomato, to market in early 2022. The seed financing will fuel the development of Phytoform’s precision crop breeding platform, which specializes in […] December 17, 2021 - 4 minutesmins - By Dan Samorodnitsky Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2021 Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts to use artificial intelligence to fuel drug discovery, with global tech investors often taking the lead. The Oxford, UK-based company Exscientia has one of the most mature artificial intelligence (AI)-focused drug discovery pipelines, alongside companies like BenevolentAI in the UK, […] October 7, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
Sponsored by Charles River 28 Sep 2021 Artificial Intelligence: A Road to Faster and Better Drug Discovery? Artificial intelligence (AI) has become a part of everyday modern life and continues to generate excitement. In this article, we will take a look at how biotechs are advancing into AI-facilitated early drug design, its real-world outcomes so far, and whether it is living up to its potential in the life science industry. AI enables […] September 28, 2021 - 6 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Opinion 31 Aug 2021 Cloud Foundations for R&D: Designing the Future of Life Sciences In recent years, artificial intelligence has been hailed as the next big thing in drug discovery. But to leverage the full potential of this technology the life sciences industry first needs to pay attention to experimental design and data collection. We embrace the latest digital technologies to enhance almost everything in our daily lives—from how […] August 31, 2021 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2021 Farxiga’s Approval Fuels Chronic Kidney Disease Comeback Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […] June 8, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 7 Jun 2021 The Post-Covid Future of AI for Drug Development With the global Covid-19 outbreak in early 2020, pharma companies and biotechs have increasingly turned to artificial intelligence to improve precision and speed in drug development. Artificial intelligence (AI), the ability of machines to learn from new input, is a broad term for a range of computing methods. Recommendation engines used by online shopping or […] June 7, 2021 - 11 minutesmins - By Matthew Williams Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Oct 2020 Top 10 Companies Combining AI and Drug Discovery in Europe Rapid advances in artificial intelligence over the last decade have the potential to revolutionize how drugs are developed. These are the top 10 companies in Europe that are working to make AI drug discovery a reality. Drug development is a slow and increasingly expensive process. Artificial intelligence (AI) has the potential to make the drug […] October 19, 2020 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 22 Jul 2020 Artificial Intelligence: A Superpower in the Fight Against Covid-19 The rapid spread of Covid-19 around the world has left drug developers with limited time to identify drug candidates to fight the virus. Amid this crisis, artificial intelligence has proven its value as a tool to make drug discovery faster and cost-effective. Drug discovery is an expensive, long-winded process. Taking a drug from discovery to […] July 22, 2020 - 8 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2020 AI Drug Discovery Firm Exscientia Closes €54M Series C UK-based Exscientia has closed a Series C financing round of €54M ($60M) to develop its artificial intelligence (AI) technology to guide drug discovery. The Danish investor Novo Holdings led the round with its first investment in the company. Additional funding also came from existing investors including drug development company Evotec and Chinese VC firm GT […] May 29, 2020 - 3 minutesmins - By David Kirk Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2020 €7M Series A To Democratize Genomics with AI-Driven Cloud Software The UK-based bioinformatics firm Lifebit Biotech has closed a €7M Series A funding round, which will help the startup to accelerate the global market expansion of its AI-driven, cloud-based genomics analysis software. The round was led by the Parisian VC firm Idinvest Partners and also included returning investors Pentech Ventures, Beacon Capital, and Connect Ventures. […] May 8, 2020 - 3 minutesmins - By Laura Cowen Share WhatsApp Twitter Linkedin Email